Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury

• Published in: Acta pharmacologica Sinica Vol. 43; no. 3; pp. 520 - 528
• Main Authors: Deng, Chao, Zhao, Lin, Yang, Zhi, Shang, Jia-jia, Wang, Chang-yu, Shen, Ming-zhi, Jiang, Shuai, Li, Tian, Di, Wen-cheng, Chen, Ying, Li, He, Cheng, Ye-dong, Yang, Yang
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.03.2022; Nature Publishing Group
• Subjects: Aging; Autophagy - physiology; Biomedical and Life Sciences; Biomedicine; Blood Coagulation Disorders - pathology; Cell death; Cell migration; Cytokine Release Syndrome - pathology; Drug development; Endoplasmic Reticulum Stress - physiology; Etiology; High mobility group proteins; HMGB1 protein; HMGB1 Protein - metabolism; Humans; Immune response; Immunology; Inflammation; Inflammation - pathology; Inflammation Mediators - metabolism; Innate immunity; Intensive care units; Internal Medicine; Medical Microbiology; Mitochondria - pathology; Multiple Organ Failure - drug therapy; Multiple Organ Failure - pathology; Pharmacology/Toxicology; Receptor for Advanced Glycation End Products - metabolism; Review; Review Article; Sepsis; Sepsis - drug therapy; Sepsis - pathology; Signal Transduction - physiology; Systemic inflammatory response syndrome; Toll-Like Receptors - metabolism; Vaccine; high mobility group box 1; inflammation; sepsis; LPS; Toll-like receptor

High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is present in almost all cells and regulates the activity of innate immune responses in both intracellular and extracellular settings. Current evidence suggests that HMGB1 plays a pivotal role in human pathological and pathophysi...